The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
The investment will improve equipment efficiency and increase safety standards at its Lestrem site
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Subscribe To Our Newsletter & Stay Updated
